Ependymomas in adults

Current Neurology and Neuroscience Reports

Volumn 10, Issue 3, 2010, Pages 240-247

  Gilbert, Mark R ^b   Ruda, Roberta ^a   Soffietti, Riccardo ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b NONE

Author keywords

Adult; Ependymoma; Pediatric; Therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; ISOTRETINOIN; LAPATINIB; TAMOXIFEN; TEMOZOLOMIDE;

ADULT; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; CYBERKNIFE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; EPENDYMOMA; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; PROGNOSIS; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CLASSIFICATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; EPENDYMOMA; EPIGENESIS, GENETIC; HUMANS;

EID: 77954944256     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0109-3     Document Type: Review

References (62)

1. Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007, 114(2):97-109.
2. Godfraind C: Classification and controversies in pathology of ependymomas. Childs Nerv Syst 2009, 25(10):1185-1193.
3. Mack SC, Taylor MD: The genetic and epigenetic basis of ependymoma. Childs Nerv Syst 2009, 25(10):1195-1201.
4. Tihan T, Zhou T, Holmes E, et al.: The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 2008, 21(2):165-177.
5. Guyotat J, Signorelli F, Desme S, et al.: Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol 2002, 60(3):255-268.
6. Metellus P, Barrie M, Figarella-Branger D, et al.: Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007, 130(Pt 5):1338-1349.
7. • Guyotat J, Metellus P, Giorgi R, et al.: Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien) 2009, 151(8):947-960. This is an important compilation of adult patients with infratentorial ependymoma.
8. • Rodriguez D, Cheung MC, Housri N, et al.: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2009, 156(2):340-351. The authors provide a comprehensive review of ependymoma from the SEER database.
9. • Reni M, Brandes AA, Vavassori V, et al.: A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004, 100(6):1221-1229. This is one of the larger series evaluating possible prognostic factors in adults with ependymoma.
10. • Armstrong TS, Vera-Bolanos E, Aldape K, et al.: Adult ependymal tumors: prognosis and the MDACC experience. Neuro Oncol 2010 (in press). This single-institution study of confirmed cases of ependymoma includes an analysis of presenting symptoms.
11. Chen CJ, Tseng YC, Hsu HL, Jung SM: Imaging predictors of intracranial ependymomas. J Comput Assist Tomogr 2004, 28 (3):407-413.
12. Mendrzyk F, Korshunov A, Benner A, et al.: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006, 12(7 Pt 1):2070-2079.
13. Tabori U, Wong V, Ma J, et al.: Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 2008, 99(7):1129-1135.
14. Snuderl M, Chi SN, De Santis SM, et al.: Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol 2008, 67(9):911-920.
15. McGuire CS, Sainani KL, Fisher PG: Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg 2009, 110(4):725-729.
16. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States; 2005.
17. Scheil S, Bruderlein S, Eicker M, et al.: Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 2001, 11 (2):133-143.
18. Jeuken JW, Sprenger SH, Gilhuis J, et al.: Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002, 197(2):238-244.
19. Modena P, Lualdi E, Facchinetti F, et al.: Identification of tumorspecific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006, 24 (33):5223-5233.
20. Gilbertson RJ, Bentley L, Hernan R, et al.: ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002, 8(10):3054-3064.
21. Lim M, Guccione S, Haddix T, et al.: alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol 2005, 36(6):665-669.
22. de Bont JM, den Boer ML, Kros JM, et al.: Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol 2007, 66(6):505-516.
23. Roma AA, Prayson RA: Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology 2006, 26(5):422-428.
24. De Bustos C, Smits A, Stromberg B, et al.: A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. J Med Genet 2005, 42(1):31-37.
25. Lukashova-v Zangen I, Kneitz S, Monoranu CM, et al.: Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007, 113(3):325-337.
26. Korshunov A, Neben K, Wrobel G, et al.: Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003, 163(5):1721-1727.
27. Suarez-Merino B, Hubank M, Revesz T, et al.: Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005, 7(1):20-31.
28. Hamilton DW, Lusher ME, Lindsey JC, et al.: Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 2005, 227(1):75-81.
29. Michalowski MB, de Fraipont F, Michelland S, et al.: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006, 166(1):74-81.
30. Waha A, Koch A, Hartmann W, et al.: Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 2004, 110(4):542-549.
31. •• Taylor MD, Poppleton H, Fuller C, et al.: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005, 8 (4):323-335. These important laboratory studies strongly support the role of radial glial cells as the stem cells for ependymomas, providing the foundation for investigations of tumor biology and creation of laboratory models.
32. Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, et al.: O6- Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother 2008, 20(2):263-268.
33. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N: Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 2005, 103(1):31-37.
34. Schwartz TH, Kim S, Glick RS, et al.: Supratentorial ependymomas in adult patients. Neurosurgery 1999, 44(4):721-731.
35. Metellus P, Figarella-Branger D, Guyotat J, et al.: Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 2008, 113 (1):175-185.
36. Healey EA, Barnes PD, Kupsky WJ, et al.: The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991, 28(5):666-671; discussion 671-672.
37. Paulino AC, Wen BC, Buatti JM, et al.: Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 2002, 25(2):117-122.
38. Ruda R, Gilbert M, Soffietti R: Ependymomas of the adult: molecular biology and treatment. Curr Opin Neurol 2008, 21 (6):754-761.
39. Merchant TE, Fouladi M: Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005, 75(3):287-299.
40. Taylor RE: Review of radiotherapy dose and volume for intracranial ependymoma. Pediatr Blood Cancer 2004, 42 (5):457-460.
41. • Merchant TE, Li C, Xiong X, et al.: Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009, 10(3):258-266. This is a seminal study regarding the utility of advanced radiation techniques for pediatric ependymoma.
42. Schild SE, Nisi K, Scheithauer BW, et al.: The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998, 42(5):953-958.
43. Salazar OM, Castro-Vita H, VanHoutte P, et al.: Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 1983, 59(4):652-659.
44. Shaw EG, Evans RG, Scheithauer BW, et al.: Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 1987, 13(10):1457-1462.
45. Gornet MK, Buckner JC, Marks RS, et al.: Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999, 45(1):61-67.
46. Brandes AA, Cavallo G, Reni M, et al.: A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 2005, 104(1):143-148.
47. Rojas-Marcos I, Calvet D, Janoray P, Delattre JY: Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology 2003, 61(7):1019-1020.
48. Chamberlain MC, Johnston SK: Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 2009, 115(20):4775-4782.
49. Rehman S, Brock C, Newlands ES: A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol 2006, 29(1):106-107.
50. Soffietti R, Constanza A, Laguzzi E, et al.: Temozolomide in rare brain tumors of the adult: a prospective study [abstract]. J Clin Oncol 2005, 23:1574.
51. Wright KD, Gajjar A: New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009, 25(10):1275-1282.
52. Green RM, Cloughesy TF, Stupp R, et al.: Bevacizumab for recurrent ependymoma. Neurology 2009, 73(20):1677-1680.
53. Peschel RE, Kapp DS, Cardinale F, Manuelidis EE: Ependymomas of the spinal cord. Int J Radiat Oncol Biol Phys 1983, 9 (7):1093-1096.
54. Nakamura M, Ishii K, Watanabe K, et al.: Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine (Phila Pa 1976) 2009, 34(21):E756-E760.
55. Gomez DR, Missett BT, Wara WM, et al.: High failure rate in spinal ependymomas with long-term follow-up. Neuro Oncol 2005, 7(3):254-259.
56. Volpp PB, Han K, Kagan AR, Tome M: Outcomes in treatment for intradural spinal cord ependymomas. Int J Radiat Oncol Biol Phys 2007, 69(4):1199-1204.
57. Schwartz TH, McCormick PC: Intramedullary ependymomas: clinical presentation, surgical treatment strategies and prognosis. J Neurooncol 2000, 47(3):211-218.
58. Shaw EG, Evans RG, Scheithauer BW, et al.: Radiotherapeutic management of adult intraspinal ependymomas. Int J Radiat Oncol Biol Phys 1986, 12(3):323-327.
59. Schultheiss TE, Stephens LC, Peters LJ: Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys 1986, 12(10):1765-1769.
60. Kocak Z, Garipagaoglu M, Adli M, et al.: Spinal cord ependymomas in adults: analysis of 15 cases. J Exp Clin Cancer Res 2004, 23(2):201-206.
61. Chamberlain MC: Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol 2001, 24 (2):117-121.
62. Fakhrai N, Neophytou P, Dieckmann K, et al.: Recurrent spinal ependymoma showing partial remission under Imatimib. Acta Neurochir (Wien) 2004, 146(11):1255-1258.